Ozempic and Wegovy both contain the same active ingredient, semaglutide, manufactured by Novo Nordisk. Despite their chemical similarity, these two medications differ significantly in their approved uses, dosing schedules, insurance coverage, and cost. Understanding these differences is essential for making an informed treatment decision.
The Same Drug, Different Approvals
Ozempic was approved by the FDA in 2017 for the treatment of type 2 diabetes. Its maximum approved dose is 2 mg per week. Wegovy was approved in 2021 specifically for chronic weight management in adults with a BMI of 30 or above, or 27 or above with at least one weight-related comorbidity. Wegovy reaches a higher maximum dose of 2.4 mg per week.
This distinction matters enormously for insurance coverage. When Ozempic is prescribed off-label for weight loss, insurance companies frequently deny coverage because it is not approved for that indication. Wegovy, with its explicit weight management approval, should theoretically be easier to get covered, though many insurers still restrict access.
Dosing Differences
Both medications follow a titration schedule where the dose is gradually increased to minimize side effects. Ozempic typically starts at 0.25 mg weekly and increases to a maintenance dose of 0.5 mg, 1 mg, or 2 mg. Wegovy starts at 0.25 mg and escalates to the target dose of 2.4 mg over approximately 16 to 20 weeks.
The higher maximum dose of Wegovy translates to greater average weight loss in clinical trials. In the STEP trials, patients on Wegovy 2.4 mg lost an average of approximately 15% of their body weight, compared to roughly 10-12% at Ozempic doses used for diabetes management.
Cost Comparison
Without insurance, Ozempic and Wegovy are both expensive. Ozempic typically costs between $850 and $1,000 per month at retail pharmacies. Wegovy is similarly priced at approximately $1,300 to $1,400 per month. With insurance coverage or manufacturer coupons, out-of-pocket costs can decrease substantially, but coverage varies widely by plan.
Side Effects Profile
Because both medications contain semaglutide, their side effect profiles are nearly identical. The most common side effects include nausea, vomiting, diarrhea, constipation, and abdominal pain. These are typically most pronounced during dose escalation and tend to diminish over time. Serious but rare side effects include pancreatitis and gallbladder problems.
For a comprehensive breakdown of side effect data from clinical trials and post-marketing surveillance, see our separate review on weight loss drug side effects.
Availability and Supply
Both Ozempic and Wegovy have experienced intermittent supply shortages since 2023. Novo Nordisk has invested heavily in expanding manufacturing capacity, and supply has improved in 2026, though some doses remain intermittently unavailable. Your prescriber should be able to advise on current availability in your area.
Which Should You Choose?
If you have type 2 diabetes and also want to lose weight, Ozempic addresses both conditions with a single medication. If your primary goal is weight management and you do not have diabetes, Wegovy is the more appropriate choice because it is FDA-approved for that indication and allows for higher dosing.
For current provider reviews and a comparison of where to get either medication, a comprehensive comparison of 29+ providers is available at GLP-1 Watchdog.
The Bottom Line
Ozempic and Wegovy are more alike than different. The best choice depends on your specific medical situation, insurance coverage, and prescriber recommendation. Do not let cost alone drive your decision. An honest conversation with a qualified healthcare provider about your goals, medical history, and insurance situation will lead to the best outcome.